---
title: "Silexion Therapeutics Announces 1-for-10 Reverse Share Split"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/288785467.md"
description: "On May 29, 2026, trading for Silexion will commence on a split-adjusted basis at the market open. This strategic adjustment aims to assist Silexion in meeting Nasdaq requirements and bolstering its market standing. The move will support the company's advancement in developing SIL204, showcasing its commitment to growth and compliance."
datetime: "2026-06-04T23:57:01.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/288785467.md)
  - [en](https://longbridge.com/en/news/288785467.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/288785467.md)
generator: "portal-rs"
---

# Silexion Therapeutics Announces 1-for-10 Reverse Share Split

On May 29, 2026, trading for Silexion will commence on a split-adjusted basis at the market open. This strategic adjustment aims to assist Silexion in meeting Nasdaq requirements and bolstering its market standing. The move will support the company's advancement in developing SIL204, showcasing its commitment to growth and compliance.

### Related Stocks

- [SLXN.US](https://longbridge.com/en/quote/SLXN.US.md)
- [SLXNW.US](https://longbridge.com/en/quote/SLXNW.US.md)

## Related News & Research

- [Silexion Therapeutics publishes corporate deck spotlighting SIL204 siRNA program targeting KRAS-driven cancers](https://longbridge.com/en/news/295325850.md)
- [Silexion reports preclinical SIL204 data supporting Phase 2/3 development in KRAS-driven cancers](https://longbridge.com/en/news/294830800.md)
- [Nykode Therapeutics to release Q2 financial results, host webcast presentation](https://longbridge.com/en/news/296641436.md)
- [IRLAB Therapeutics to webcast interim report presentation](https://longbridge.com/en/news/296470410.md)
- [Pelthos Therapeutics announces annual shareholder meeting](https://longbridge.com/en/news/296270309.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**